Thursday, November 6, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Analyst Reiterates Buy Rating and Sets Price Target for Plexus

Elaine Mendonca by Elaine Mendonca
March 8, 2024
in Breaking News
0
SNDR stock news
0
SHARES
2
VIEWS
Share on FacebookShare on Twitter

On March 8, 2024, analyst David Williams from Benchmark reiterated a Buy rating on Plexus (NASDAQ: PLXS) and set a price target of $110. This reaffirmation reflects Benchmark’s optimistic view on Plexus, showing strong confidence in the company’s future performance and growth prospects.

Plexus Corp (PLXS) Stock Sees Slight Increase on March 8, 2024: Is This the Start of a New Trend?

On March 8, 2024, Plexus Corp (PLXS) experienced a slight increase in its stock performance. The stock opened at $96.55, which was $1.09 higher than its previous close. Throughout the trading day, the price of PLXS shares continued to rise, ending the day with a $0.28 increase, a 0.29% rise from the previous close. Investors may be keeping a close eye on PLXS to see if this upward momentum can be sustained in the coming days. It will be important to monitor any further price movements to determine if this is a temporary blip or the start of a more significant trend.

Plexus Corp (PLXS) Stock Performance Fluctuates on Latest Financial Data

On March 8, 2024, Plexus Corp (PLXS) saw some fluctuations in its stock performance based on the latest financial data provided by CNN Money. The total revenue for Plexus Corp in the past year was reported at $4.21 billion, showing a 10.47% increase compared to the previous year. However, in the first quarter of the current fiscal year, the total revenue dropped to $982.61 million, marking a 4.04% decrease from the previous quarter. Similarly, the net income for Plexus Corp was $139.09 million in the past year, remaining flat compared to the previous year. However, in the first quarter of the current fiscal year, the net income decreased to $29.21 million, representing a significant 27.44% decline from the previous quarter. Furthermore, the earnings per share (EPS) for Plexus Corp was reported at $4.95 in the past year, showing no change compared to the previous year. However, in the first quarter of the current fiscal year, the EPS dropped to $1.04, marking a substantial 27.54% decrease from the previous quarter. Overall, the fluctuations in Plexus Corp’s financial performance, particularly the decrease in revenue, net income, and EPS in the first quarter of the current fiscal year, may have impacted its stock performance on March 8, 2024. Investors and analysts will likely closely monitor the company’s future financial reports to assess its growth prospects and potential for stock price recovery.

Tags: PLXS
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Finance_Budgeting (1)

Analyst Reaffirms Buy Rating for Bristow Group with 40 Price Target

Technology Blockchain Stock Market Today

Analyst Bullish on Akamai Technologies Raises Price Target to 140

Finance_Commercial (2)

Whales Show Positive Outlook on Walmart Stock Options

Recommended

Marvell Technology Stock

Marvell Technology Emerges as Key Player in AI Infrastructure Boom

1 month ago
Novo Nordisk Stock

Danish Pharma Giant Novo Nordisk Faces Diverging Analyst Views

1 month ago
Finance_Investment (5)

Anticipation Builds as FirstService Prepares to Release Quarterly Earnings Report

2 years ago
Viking Therapeutics Stock

Acquisition Speculation Fuels Viking Therapeutics Stock Surge

1 month ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple Applovin BioNTech Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Lockheed Marvell Technology META Micron Microsoft MP Materials MSCI World ETF NIO Nvidia Ocugen Opendoor Oracle Oxford Lane Capital Palantir PayPal Plug Power QuantumScape Realty Income Robinhood Rocket Lab USA Salesforce Strategy Super Micro Computer Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

DuPont Faces Critical Test as Quarterly Results Loom

Sarepta Therapeutics Shares Plummet Following Critical Clinical Trial Failure

Emerson Electric’s Strategic Pivot Faces Market Scrutiny

EU Grant Provides Critical Boost for LanzaTech’s Carbon Recycling Technology

Is Darden Restaurants Facing a Critical Test?

Critical Juncture for USA Rare Earth as Earnings and Chinese Export Curbs Collide

Trending

BioNTech Stock
Analysis

BioNTech’s Crossroads: Navigating Losses Amid Cancer Research Promise

by Andreas Sommer
November 6, 2025
0

BioNTech presents investors with a complex financial picture marked by contradictory signals. The German biotech firm reported...

Illumina Stock

China Lifts Export Ban on Illumina’s DNA Sequencers, Sparking Market Rally

November 6, 2025
Iovance Stock

Iovance Faces Critical Test as Q3 Earnings Approach

November 6, 2025
DuPont de Nemours Stock

DuPont Faces Critical Test as Quarterly Results Loom

November 6, 2025
Sarepta Therapeutics Stock

Sarepta Therapeutics Shares Plummet Following Critical Clinical Trial Failure

November 6, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • BioNTech’s Crossroads: Navigating Losses Amid Cancer Research Promise
  • China Lifts Export Ban on Illumina’s DNA Sequencers, Sparking Market Rally
  • Iovance Faces Critical Test as Q3 Earnings Approach

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com